Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway.

ABSTRACT:

Ethnopharmacological relevance

Acute lung injury (ALI) is one of the fatal complications of respiratory virus infections such as influenza virus and coronavirus, which has high clinical morbidity and mortality. Jinhua Qinggan granules (JHQG) has been approved by China Food and Drug Administration in the treatment of H1N1 influenza and mild or moderate novel coronavirus disease 2019 (COVID-19), which is an herbal formula developed based on Maxingshigan decoction and Yinqiao powder that have been used to respiratory diseases in China for thousands of years. However, the underlying mechanism of JHQG in treating infectious diseases remains unclear.

Aim of the study

This study investigated the effects of JHQG on neutrophil apoptosis and key signaling pathways in lipopolysaccharid

SUBMITTER: Zhu Y 

PROVIDER: S-EPMC9523948 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature